SynDevRx
PrivateLast Round
Series C
Dec 22, 2025
Total Funding Raised
$31.33M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
SynDevRx is a clinical-stage biotechnology company that develops treatments for cancers sensitive to metabolic hormones.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SynDevRx Comparables
Compare SynDevRx with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Partex | 80% | |
| Kalohexis | 79% | |
| Actimed Therapeutics | 78% |
SynDevRx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Dec 22, 2025 | ||||
| Grant | Jan 9, 2025 | ||||
| VC Round | Nov 4, 2024 | ||||
| Grant | Aug 31, 2022 | ||||
| Series B | Jan 25, 2022 | ||||
Series B | Jan 9, 2020 |
Key People
Founding team and executive leadership
SynDevRx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| U.S. Department of War | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 190% MoM.
- Dec 22, 2025
Raised $6.4M in Series C funding.
Recent news
Latest coverage and updates
- attends_eventOct 20, 2026
SynDevRx, Inc. is scheduled to present interim metabolic and biomarker data from the AMELIA(TM)-1 trial in breast cancer patients at ESMO 2026 in Spain on Oct 24th '26.
- attends_eventOct 20, 2026
SynDevRx, Inc. announces that interim biomarker data from its ongoing AMELIA(TM)-1 clinical trial is scheduled for presentation in poster 1862P at the European Society for Medical Oncology (ESMO) Congress 2026 in Spain on Oct 24th '26.
SynDevRx Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about SynDevRx's valuation, stock price, and market status.
Is SynDevRx a public or private company?
SynDevRx is a private company.
What is the current stock price of SynDevRx?
SynDevRx is a private company, so its shares have no public market price. Caplight tracks SynDevRx's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is SynDevRx worth (valuation)?
Valuation information for SynDevRx is not publicly available.
Can I buy SynDevRx stock?
SynDevRx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was SynDevRx's last funding round?
SynDevRx's most recent funding round was Series C on December 22, 2025.
Who are the main investors in SynDevRx?
Key investors in SynDevRx include U.S. Department of War.
Will SynDevRx IPO soon?
No public IPO plans have been announced for SynDevRx.
How can I track SynDevRx secondary market activity?
Caplight tracks bids, offers, and trades in SynDevRx's shares on secondary markets.